TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY
The clinical course of CLL and outcomes for patients vary widely, largely based on the presence of individual predictive and other risk factors. In recent years the identification of cytogenetic abnormalities and their subsequent incorporation into traditional clinical staging systems has refined clinicians’ ability to determine patient prognosis, and based on the improved understanding of the biology of CLL, a number of novel agents and therapeutic strategies have been investigated. Some of these efforts have proven successful and are already available for use in the clinic, but along with these many exciting advances, vexing questions and clinical challenges are emerging simultaneously. To bridge the gap between research and patient care, this program features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES

Recall the incidence, prognostic significance and clinical implications of select biomarkers and chromosomal abnormalities that may be associated with a diagnosis of CLL, and use this information to develop evidence-based testing algorithms in general oncology practice.
Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering clinical presentation, biomarker profile and psychosocial status.
Implement a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of CLL.
Appreciate recent therapeutic advances and related FDA approvals in CLL, and discern how these agents can be appropriately integrated into routine clinical practice.
Review emerging clinical data on the efficacy and safety of the recently FDA-approved antibody-drug conjugate moxetumomab pasudotox for hairy cell leukemia.
Evaluate available data with and consider the potential clinical roles of novel agents and regimens that may provide treatment options for additional patients beyond those for whom they were initially indicated.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Prof John G Gribben, MD, DSc, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Queen Mary University of London
Charterhouse Square
London, United Kingdom

Advisory Committee: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Janssen Biotech Inc, Kite Pharma Inc, Novartis, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc; Consulting Agreements: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Janssen Biotech Inc; Data and Safety Monitoring Board: Acerta Pharma — A member of the AstraZeneca Group.

Jennifer R Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Biogen Idec, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Loxo Oncology, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sun Pharmaceutical Industries Ltd, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc, Verastem Inc; Contracted Research: Gilead Sciences Inc, Sun Pharmaceutical Industries Ltd, Verastem Inc; Data and Safety Monitoring Board: Invectys, MorphoSys.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP/Acerta Pharma — A member of the AstraZeneca Group, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Pharmacyclics LLC, an AbbVie Company.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: December 2018
Expiration date: December 2019